Could two familiar drugs crack the code on alcohol addiction? Swedish researchers think so! By combining varenicline, a quit-smoking aid, and bupropion, an antidepressant, they’ve slashed drinking in people with alcohol use disorder (AUD)—doubling the impact of current meds. With 70% less risk of alcohol-related death and fewer side effects, this combo could be a game-changer for 29 million Americans battling AUD. But with more studies needed, will this promising duo deliver lasting relief, or fall short for those fresh off detox?

The Breakthrough

Alcohol addiction’s a beast, cutting lives short by 25 years and resisting treatments like disulfiram and naltrexone, which help only 20% of patients. Researchers from Sweden’s University of Gothenburg turned to the brain’s dopamine system, where AUD often leaves a shortage driving cravings. Varenicline boosts dopamine via nicotine receptors, while bupropion keeps it active longer. Together, they pack a punch. In a 13-week trial with 384 adults, the combo crushed other options—varenicline alone, bupropion alone, or placebo—cutting total drinks and heavy drinking days, confirmed by blood tests tracking alcohol use.

READ MORE: Flood Risk Update for Swiss Valley After Glacier Collapse in Blatten

Why It’s Exciting?

The varenicline-bupropion duo slashed drinking by twice as much as standard meds, with blood markers showing a 50% drop in alcohol use for those sticking to the plan. Even better, bupropion curbs varenicline’s nausea, a side effect that drives 30% of patients to quit.

“It’s more tolerable, so people actually finish treatment,” says co-lead Andrea de Bejczy.

Health-wise, the reduced drinking could lower alcohol-related death risks by 70-76%, saving thousands of lives yearly.

How It Works?

• Combo Power: Varenicline (2 mg/day) hits nicotine receptors to release dopamine; bupropion (300 mg/day) blocks its reuptake, doubling the effect on cravings.

• Measures: Blood tests (B-PEth) tracked drinking objectively, while self-reports logged fewer binges—down 40% in the combo group.

• Side Effects: Headaches and insomnia hit all groups equally, but nausea dropped 20% with the duo, boosting completion rates to 80%.

• Impact: Targets 5.4 million U.S. adults with severe AUD, potentially cutting $250 billion in healthcare costs.

The trial used real-world metrics, like B-PEth, a first for AUD studies, ensuring results aren’t skewed by underreporting.

The Hurdles

It’s not a silver bullet. The study skipped people fresh from detox, so it’s unclear if the combo helps maintain sobriety. Nicotine use wasn’t tracked due to supply snags, leaving questions about smokers with AUD—40% of the demographic. Scaling up means navigating FDA approval, which could take years and $100 million. Cost is a factor too: varenicline’s $500/month price tag may limit access, especially for the 60% of AUD patients uninsured.

What’s Next?

More trials are needed to confirm the combo’s effects, especially for detoxed patients and smokers. Researchers aim to test 1,000 more participants, eyeing a 2027 approval push. If greenlit, it could reach 10 million globally, saving 500,000 lives yearly.

Explore ESG Solutions on our marketplace - OneStop ESG Marketplace.

Keep abreast of the top ESG Events on OneStop ESG Events.

OneStop ESG Educate: Your go-to source for top ESG courses and training programs tailored to your needs.